Pharmaceutical News

This undated file photo provided by Barr Pharmaceuticals Inc., shows a package of Plan B One-Step, an emergency contraceptive.

The Supreme Court sided with government regulators in an important case involving the pharmaceutical industry and patent law.

The U.S. Supreme Court ruled on Monday regulators can challenge deals between brand-name drug companies and generic rivals that delay cheaper medicines from going on sale, which regulators say increase costs to consumers by billions of dollars.

A Supreme Court ruling issued Monday that works against generic-drug maker Actavis Inc. took a bite out of the company's shares in the minutes after it was issued, but others in the company's peer group didn't seem to be affected much by the decision.

Drugmakers can be sued for paying rivals to delay low-cost versions of popular medicines, the U.S. Supreme Court said in a decision that rewrites the rules governing the release of generic drugs.

As the world of big drug companies streamlines operations by shrinking research-and-development staffs and outsourcing tasks amid patent losses on key medicines, the benefit is two-fold for specialty firms contracted to take on the work.

The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats.

AN IRISH engineering company is leading the fight against counterfeit medicines, working with the pharmaceutical industry at home and abroad to implement sophisticated systems to guarantee drugs are genuine.

'You can't say research and innovation are your absolute priorities and then not protect ideas,' says Christopher Viehbacher, CEO of pharma giant Sanofi.

Project Description: MarketLines' Barr Laboratories, Inc. Mergers & Acquisitions , Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions , divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Barr Laboratories, Inc.

I have a few questions for all you women out there. Be honest. Is your libido a bit less lively than it used to be? Are there times when you'd rather watch reruns of Mad Men than have an intimate encounter with your husband? When engaged in foreplay, do you ever think about the grocery list? When you read surveys claiming that average married ... (more)

Bristol-Myers Squibb Company and AbbVie today announced updated efficacy and safety data from a small, randomized Phase 2, open-label study in patients with previously-treated multiple myeloma that evaluated two doses of the investigational monoclonal antibody elotuzumab in combination with lenalidomide and low-dose dexamethasone.

Emerging markets have heated up for every industry, but the world's biggest pharmaceutical players have approached the challenges of capturing these promising markets in unique ways.

AARP's Public Policy Institute have released a new Rx Price Watch report examining efforts by Pfizer to reduce the impact of generic competition for the popular anti-cholesterol drug Lipitor.

Patheon Inc., a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, today announced that it will be hosting a complimentary seminar on "Formulation, Funding and First-in-Man: A Stepwise Guide to Clinical Success".

Growing Stock Report expands its NASDAQ Gainers Watch List adding ACADIA Pharmaceuticals Inc. and Mylan, Inc. .

After plaintiffs-appellees' case was removed from state court on the basis of diversity jurisdiction, the district court allowed the joinder of several non-diverse defendants and remanded the case.

Today's hospitals consider physician relationships critical to their success in an accountable care environment - whether through direct employment or affiliation with independent community physicians.

Pfizer Inc. reached a $2.15 billion settlement with Teva Pharmaceutical Industries and Sun Pharmaceutical Industries in a nearly 10-year patent infringement legal battle.

With the health care reform legislation expected to provide coverage for approximately 32 million previously Americans starting in 2014, the pharmaceutical industry should derive benefit from the new law taking effect - even accounting for the rising costs these companies might face because of this legislation.